Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

Dow Jones
04 Apr
 

By Connor Hart

 

Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading.

CXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading.

Sangamo Therapeutics entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

April 03, 2025 19:37 ET (23:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10